Cardiovascular effects of methylphenidate, risperidone, and their combination in children and adolescents with attention-deficit/hyperactivity disorder: a prospective 3-month observational study
4 affiliations
- 1Clinical Research Development Unit of Advanced Medicine, Qazvin University of Medical Science, Qazvin, Iran
- 2Department of Epidemiology, School of Public Health, University of Medical Sciences, Tehran, Iran
- 3Non-communicable Diseases Research Center, Research Institute for Prevention of Non-communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran
- 4Students’ Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran
Abstract
Background: We aimed to evaluate changes in hemodynamic parameters and electrocardiographic (ECG) indices related to ventricular arrhythmia risk after three months of treatment with methylphenidate (MPH), risperidone (RIS), or their combination in children and adolescents with ADHD.
Methods: A total of 150 children and adolescents with DSM-5-diagnosed ADHD were prospectively enrolled at Qods Hospital. Participants received methylphenidate (n = 50), risperidone (n = 50), or combination therapy (n = 50). Cardiovascular outcomes were assessed using age- and weight-adjusted two-way repeated-measures ANCOVA to evaluate changes over time and differences among treatment groups.
Results: Significant group × time interactions were observed for systolic blood pressure, diastolic blood pressure, heart rate, and QTc interval after adjustment for baseline age and weight. After three months, systolic and diastolic blood pressure increased in the methylphenidate and combination therapy groups, while heart rate showed an overall increase, with the greatest rise observed in the methylphenidate group. QTc interval increased over time across all treatment groups, with the largest prolongation observed in the combination therapy group (377.9 ± 25.4 to 424.5 ± 24.9 ms). However, mean QTc values remained below commonly accepted thresholds for clinically significant QT prolongation, and no significant longitudinal changes were observed in QRS duration or PR intervals.
Conclusion: Treatment with methylphenidate, risperidone, and combination therapy was associated with modest changes in heart rate, blood pressure, and QTc interval over three months. These findings highlight the importance of baseline and follow-up cardiovascular monitoring in children and adolescents receiving ADHD medications.
Related
- Risperidone for children with attention-deficit/hyperactivity disorder and severe behavioral dysregulation: a randomized placebo-controlled assessor-blinded trial.
- Expert Review on the Use of Methylphenidate in Children and Adult With Epilepsy and Attention Deficit Hyperactivity Disorder
- Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone
- Bringing Cardiovascular Prevention into the Community: Protocol for an Observational Study of a Mosque-Based Health Initiative Combining Education and Cardiovascular Screening
- Optimizing Cardiovascular Risk in PLWH: Real-World Efficacy and Lipid Kinetics of Fixed-Dose Combination Rosuvastatin Ezetimibe.
BibTeX
@article{oveisi2026cardiovascular,
title = {{Cardiovascular effects of methylphenidate, risperidone, and their combination in children and adolescents with attention-deficit/hyperactivity disorder: a prospective 3-month observational study}},
author = {Sonia Oveisi and Elahe Jafari and Mohamad Mahdi Bahari and Mina Farshidgohar},
journal = {BMC Pediatrics},
year = {2026},
month = aug,
doi = {10.1186/s12887-026-07479-x},
url = {https://doi.org/10.1186/s12887-026-07479-x},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cardiovascular effects of methylphenidate, risperidone, and their combination in children and adolescents with attention-deficit/hyperactivity disorder: a prospective 3-month observational study
AU - Sonia Oveisi
AU - Elahe Jafari
AU - Mohamad Mahdi Bahari
AU - Mina Farshidgohar
PY - 2026
DA - 2026/08/06
JO - BMC Pediatrics
DO - 10.1186/s12887-026-07479-x
UR - https://doi.org/10.1186/s12887-026-07479-x
AB - Background: We aimed to evaluate changes in hemodynamic parameters and electrocardiographic (ECG) indices related to ventricular arrhythmia risk after three months of treatment with methylphenidate (MPH), risperidone (RIS), or their combination in children and adolescents with ADHD. Methods: A total of 150 children and adolescents with DSM-5-diagnosed ADHD were prospectively enrolled at Qods Hospital. Participants received methylphenidate (n = 50), risperidone (n = 50), or combination therapy (n = 50). Cardiovascular outcomes were assessed using age- and weight-adjusted two-way repeated-measures ANCOVA to evaluate changes over time and differences among treatment groups. Results: Significant group × time interactions were observed for systolic blood pressure, diastolic blood pressure, heart rate, and QTc interval after adjustment for baseline age and weight. After three months, systolic and diastolic blood pressure increased in the methylphenidate and combination therapy groups, while heart rate showed an overall increase, with the greatest rise observed in the methylphenidate group. QTc interval increased over time across all treatment groups, with the largest prolongation observed in the combination therapy group (377.9 ± 25.4 to 424.5 ± 24.9 ms). However, mean QTc values remained below commonly accepted thresholds for clinically significant QT prolongation, and no significant longitudinal changes were observed in QRS duration or PR intervals. Conclusion: Treatment with methylphenidate, risperidone, and combination therapy was associated with modest changes in heart rate, blood pressure, and QTc interval over three months. These findings highlight the importance of baseline and follow-up cardiovascular monitoring in children and adolescents receiving ADHD medications.
SN - 1471-2431
ER -